Status:
RECRUITING
Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-RFA Recurrence in HCC Patients
Lead Sponsor:
Tian'an Jiang
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
Brief Summary
Background A predictive model for post radiofrequency ablation (RFA) recurrence in patients with Hepatocellular carcinoma (HCC) that incorporates variables like sleep quality and psychological factors...
Detailed Description
Liver cancer is one of the most common malignant tumors globally, ranking sixth in incidence among all types of malignancies and third in mortality1. There were 905,700 new cases and 830,200 deaths fr...
Eligibility Criteria
Inclusion
- ① Diagnosed as primary HCC according to the diagnostic criteria for primary liver cancer in China; ② Either a solitary tumor with a diameter less than 5 cm or 2-3 tumors each with a maximum diameter less than 3 cm; ③ RFA as the initial treatment; ④ Agreed to participate in the study and submitted the completed questionnaire survey; ⑤ A follow-up period exceeding 6 months after ablation.
Exclusion
- ① Vascular invasion or extrahepatic metastasis before ablation; ② Presence of intractable ascites or hepatic encephalopathy; ③ Severe hepatic and renal dysfunction or other substantial organ disorders; ④ Active infections before or after ablation; ⑤ A history of other malignancies; ⑥ Failure to submit a completed questionnaire survey; ⑦ Lost to follow-up before reaching an outcome.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2024
Estimated Enrollment :
6000 Patients enrolled
Trial Details
Trial ID
NCT06577272
Start Date
September 1 2024
End Date
November 1 2024
Last Update
August 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China, 310003